A single dose of a new small-interfering RNA therapeutic, lepodisiran, reduced the level of harmful risk factor lipoprotein(a) [Lp(a)] by up to 94% for nearly 1 year in subjects with high Lp(a) concentration and without cardiovascular disease, according to a new study.